^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Zydelig (idelalisib) (PI3Kδ inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma...Idelalisib monotherapy is included as an option for relapsed/refractory therapy, regardless of patient's age or comorbidities.
